Compass Therapeutics’ CTX-009 Gains FDA Fast Track Status
Company Announcements

Compass Therapeutics’ CTX-009 Gains FDA Fast Track Status

Compass Therapeutics (CMPX) has issued an announcement.

Compass Therapeutics, Inc. has announced a significant advancement for its leading drug candidate, CTX-009, which has been granted Fast Track Designation by the U.S. FDA. This promising bispecific antibody, used in combination with paclitaxel, aims to improve treatment for patients with biliary tract cancer, potentially speeding up the development process and review of this innovative therapy. Investors and those following the biotech sector may find this news particularly encouraging as it represents a critical step forward in the drug’s path to market.

For detailed information about CMPX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCompass Therapeutics Reports Q3 2024 Financials and Clinical Progress
TheFlyCompass Therapeutics price target raised to $7 from $5 at Ladenburg
TheFlyCompass Therapeutics reports Q3 EPS (8c), consensus (11c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App